JNJ 39758979

Drug Profile

JNJ 39758979

Alternative Names: JNJ-39758979

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antiasthmatics; Antipruritics; Antirheumatics; Pyrimidines; Pyrrolidines; Skin disorder therapies
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Atopic dermatitis; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 May 2012 Johnson & Johnson withdraws a phase II trial in Asthma prior to enrolment (NCT01493882)
  • 13 Jan 2012 Johnson & Johnson suspends a phase II trial in Rheumatoid arthritis in US (NCT01480388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top